OGM enabled detailed molecular characterization of rare SVs, such as identification of ELL as the gene partner for KMT2A in a case of WT1 mutated MDS with t(11;19)(q23;p13.1). The gene discussed is ELL; the disease is myelodysplastic syndrome.